NDUFAB1 and neoplasm: Named “human alpha‐lactalbumin made lethal to tumor cells (HAMLET)”, this complex is currently under investigation in an early phase clinical trial.[7] The monomeric form of alpha‐lactalbumin was reported to be inactive for anticancer activity,[8] but alpha‐lactalbumin could nevertheless provide a good lead for developing a computer‐generated peptide library, followed by deployment of in silico ACP screening and experimental validation of ACP candidates.